Bisu's "lab-on-a-chip" urine and saliva analyzer is intended for both consumer and astronaut use.

TOKYO - December 1, 2022 - (Newswire.com)

Traveling in space leads to bone loss, muscle loss, and an increased risk of kidney stone formation, often starting within the first 24 hours of spaceflight as calcium levels in bone and tissue decrease and are expelled in urine. A new research experiment, selected for inclusion in the upcoming Polaris Dawn spaceflight mission, aims to show if monitoring the first urine sample in the morning could provide a simple way to track astronaut health in space. If successful, the research will provide a pathway to use compact, new inflight monitoring techniques. The day's first urine sample typically has the highest urine calcium levels in the day and taking measurements from this sample might offer a workable way to assess in-flight bone loss and kidney stone risk. As both space accessibility and long-duration human spaceflights increase, keeping crews healthy by providing personalized, targeted countermeasures will be essential. This will require small, easy-to-use, low-power devices that can provide actionable information using easily obtainable samples of urine or saliva, such as a first-morning void.

Bisu is a startup that helps people improve their health and fitness through lab-grade testing at home. Working with former astronaut Jay Buckey, MD, Professor of Medicine and Director of the Space Medicine Innovations Lab at the Geisel School of Medicine at Dartmouth, Bisu will support the post-flight analysis of first-morning void urine samples gathered from the Polaris Dawn crew to assess the effect of spaceflight on markers of bone loss, muscle loss, and kidney stone risk. If successful, this research could pave the way for inflight monitoring with new technologies, such as the microfluidic urine and saliva analyzer Bisu has developed. Because weightlessness affects people differently, this kind of in-flight monitoring could provide targeted countermeasures.

"People will be spending longer times in space, and they may not be able to do the extensive countermeasure programs currently used on the space station," says Prof. Jay Buckey. "We need simple ways to monitor people while they are in space so that the countermeasure program can be targeted to each person's individual needs. This research puts us on the path toward that."

"We're delighted to be working with Polaris Dawn and Prof. Buckey on this pioneering research," says Daniel Maggs, co-founder & CEO at Bisu. "This research reflects Bisu's commitment to advancing human health by making valuable health data accessible to all - whether on Earth or in space."

About Polaris Dawn

Polaris Dawn is the first of the Polaris Program's three human spaceflight missions. SpaceX is targeting no earlier than March 2023 for Falcon 9's launch of Dragon and the Polaris Dawn crew from Launch Complex 39A at NASA's Kennedy Space Center in Florida. Polaris Dawn endeavors to reach the highest Earth orbit ever flown, attempt the first-ever commercial spacewalk, conduct extensive research to further our understanding of human health on Earth and during future long-duration spaceflights, and test Starlink's laser-based communications in space. For more information, visit polarisprogram.com/dawn.

About Bisu

Bisu is a healthtech startup that provides personalized, preventative advice at home, through nutrition and hormone tests using microfluidic "lab-on-a-chip" technology. In late 2021, Bisu announced a $3.2m seed round and collaboration with ASICS, took home the Good Design Award in the wellness category, and won the US Sports & Fitness Industry Association's startup challenge.

Bisu's flagship product, Bisu Body Coach, is currently in beta and can be applied for at www.bisu.com.

About the Space Medicine Innovations Laboratory at the Geisel School of Medicine at Dartmouth

The Space Medicine Innovations Laboratory is devoted to solving biomedical problems presented by long-duration space flight. The lab has performed work on bone loss, decompression sickness, motion sickness, and psychological countermeasures for isolation and confinement. The lab also advances work that began with NASA into other areas of research. 

Please address all press inquiries to [email protected].

Contact Information:
Daniel Maggs
[email protected]




Press Release Service by Newswire.com

Original Source: Home Health Lab Startup Bisu Collaborates With Polaris Dawn to Develop New Ways to Monitor Astronaut Health

LEXINGTON, Ky. - December 1, 2022 - (Newswire.com)

Thynk Health and Riverain, pioneers in the healthcare artificial intelligence space, have announced a partnership between their platforms to fight lung cancer with the world's most advanced technologies. Combining all the latest technologies, including CAD, Machine Learning, clinical NLP, recurrent neural networks, and artificial intelligence, this partnership offers an unprecedented opportunity for lung cancer screening and pulmonary nodule management.

Thynk Health is the complete cancer screening and incidental finding management solution. Utilizing state-of-the-art artificial intelligence and deep learning algorithms, Thynk Health seamlessly integrates with EHRs and health systems to mine structured and unstructured data, organizing it in powerful, simple dashboards. With advanced automation and analytics, healthcare systems are empowering their cancer screening programs with actionable intelligence to be more effective and efficient.

"Radiologists are experiencing AI as an adjunctive tool, rather than the job-stealing technology previously warned by futuristic writers," said Joey Bargo, Thynk Health Co-Founder and Chief Product Officer. "This is evident in the ability to have a second set of eyes when looking for small or hilar region pulmonary nodules. When utilized in combination with advanced deep learning for language abstraction from reporting, AI technology is even more effective, allowing for radiologists to use traditional workflows, rather than archaic and cumbersome second workstation solutions." 

Riverain Technologies is on a mission to revolutionize radiology by changing one in three delayed cardio-thoracic disease diagnoses to none in three. Using unique suppression technology, the ClearRead imaging interpretation solutions with Clear Visual Intelligence™ (CVI™) create an unobstructed view within the existing workflow so radiologists can focus on what matters to detect, precisely characterize, and report findings. Imaging interpretation with CVI™ moves radiologists beyond standard background-impaired imaging interpretation to allow focus on the actionable data to correctly and quickly detect cardio-thoracic diseases with newfound Certainty of Search™. 

"Radiology is the gateway to finding, assessing, and reporting the course of many diseases, especially lung cancer, including evaluating the response to treatment. Yet the exploding volume and complexity of imaging interpretation, especially in chest CT scans, is creating a crisis for both patients and radiologists that must be addressed—now," said Steve Worrell, Riverain CEO. "This partnership will bring cutting-edge solutions to improve nodule detection and increase efficiencies in nodule management." 

"The power of Thynk Health's AI-driven analytics abstracted from healthcare EHRs combined with Riverain's ClearRead suite significantly improves the ability to detect lung disease and changes the lives of patients, creating a comprehensive solution for lung cancer screening and pulmonary nodule management that offers healthcare systems a new level of patient care and growth and provides a new level of automation in the lung nodule diagnostic process," said Jeff Timbrook, Thynk Health CEO.

Lung Cancer continues to be the leading cause of cancer death among men and women, making up almost 25 percent of all cancer deaths (more than colon, breast, and prostate cancers combined). In 2022 the American Cancer Society estimates 236,740 new cases of lung cancer will be diagnosed, and 130,180 deaths from lung cancer will occur. Thynk Health and Riverain's partnership opens a new level of opportunity for healthcare systems to identify at-risk populations and diagnose and treat those populations when in early stages, significantly increasing survival rates. With advanced technology companies, healthcare systems, and communities partnering together, we can and we will win the fight against lung cancer.
 

About

The Thynk Health platform optimizes data-driven workflows and provides operational and clinical analytics for lung cancer screening programs and other quality initiatives. Thynk Health's Lung Module automatically identifies patients at risk for lung cancer, automates patient data and ACR submission, automates patient communications, automates tracking of incidental findings, engages providers, provides actionable LCS reports, and offers pulmonary nodule tracking. Thynk Health is EHR agnostic and integrates with existing hospital systems (EHR, DICOM, PACS, scheduling, and more). Learn more at thynkhealth.com

The Riverain ClearRead solution eliminates obstructions that often stand in the way of accurately and efficiently detecting disease in thoracic (lung) CT and XR images. Powered by machine learning and advanced modeling, our patented, FDA-cleared, and clinically proven software tools are deployed in the clinic or the cloud and are powered by the most advanced AI methods available to the medical imaging market. Learn more at riveraintech.com

Contact Information:
Thomas Croce
Marketing Manager
[email protected]
1-855-633-6963 x 711


Press Release Service by Newswire.com

Original Source: Thynk Health and Riverian Partner to Fight Lung Cancer With Advanced AI and Deep Learning Technologies

The only zero-prep, full-montage, rapid EEG solution for clinical use now offers near real-time notification of ongoing seizures by using reliable FDA cleared seizure detection software

SANTA CLARA, Calif. - December 1, 2022 - (Newswire.com)

Zeto, Inc., an innovative EEG brain monitoring company, announced today the integration of FDA cleared seizure detection and trending algorithms developed by encevis, now available as part of the Zeto EEG platform. encevis is powered by the AIT Austrian Institute of Technology, a renowned research and technology organization in Europe, and their EEG analysis software is widely utilized and peer reviewed by physicians across the world.

These new tools will help Zeto's customers speed up EEG reviews. The trending module graphically reports several hours of EEG into a simple display to allow rapid assessment of brain states. The seizure detection component offers high sensitivity with low false alarm rates, matching and in parts surpassing industry benchmarks. Proven by three independent clinical publications, and harvesting the power of AI and deep learning, the software provides a detailed overview of seizures and suspicious EEG activity.

"According to current studies, 18% of critically ill patients with serious brain diseases suffer from unrecognized non-convulsive epileptic seizures, frequently leading to neurological disabilities. The joint efforts of Zeto and encevis will make EEG faster to read by automatically detecting and orienting the reader to abnormalities. Seizures will be automatically detected and marked in the EEG for review. Near real-time detection notifies medical staff about patients with ongoing clinical seizures," said Dr. Tilmann Kluge, head of Medical Signal Analysis of AIT.

"We are excited to integrate encevis' seizure detection and trending tools into our platform. Collaborative projects such as this ensure a seamless user experience and enable healthcare providers to offer the best care to their patients at an affordable price," said Florian Strelzyk, Chief Sales Officer at Zeto.

Zeto EEG analysis features will continue to evolve as more third party integrations become available. Zeto is committed to driving innovation in brain monitoring by opening its platform to strategic projects and partnerships that empower health care providers to diagnose their patients rapidly and more effectively.

About Zeto

Zeto, Inc. is an award-winning, privately held medical technology company located in Santa Clara, California, that is focused on transforming the way electroencephalography (EEG) is performed at hospitals and clinics. Zeto's revolutionary FDA-cleared EEG headset and cloud platform bring the traditional EEG procedure to the 21st century. 

To learn more about Zeto's products, including the remote EEG monitoring, please visit: https://zeto-inc.com or email us at [email protected].

About encevis

encevis is a part of the AIT Austrian Institute of Technology, Austria's largest non-university research institute, is among the European research institutes a specialist in the key infrastructure issues of the future.

Learn more: https://www.encevis.com

Contact Information:
Irina Nazarova
Marketing Manager
[email protected]
9174351226


Press Release Service by Newswire.com

Original Source: Zeto Implements encevis' Seizure Detection and Trending Algorithms

NEW YORK - December 1, 2022 - (Newswire.com)

Obesity has become a rising public health concern with its association with diseases, including type 2 diabetes, cardiovascular disease, non-communicable respiratory diseases, and cancers. As per the data predicted by the World Obesity Atlas 2022, one billion people globally, including 1 out of 5 women and 1 out of 7 men, will be living with obesity by 2030. With high rates of obesity, it is important to find a solution. That's where weight loss clinics like NextMed enter.

Significance of Medical Weight Loss Clinics

NextMed provides comprehensive weight loss services. This includes medical evaluations, nutritional counseling, lifestyle advice, and physical activity programs. The popular weight loss clinic offers prescription medications or other treatments to help people achieve their goals. In addition to helping individuals lose weight, they provide constant support & assistance to maintain a healthy lifestyle.

There are many different reasons why people choose to visit a weight loss clinic. For some, it may be a last resort after trying other weight loss methods without success. Others may feel more comfortable in a group setting or appreciate the support and motivation these clinics can provide.

Weight loss clinics are an essential resource for those struggling with obesity. They can help people lose weight in a safe and controlled environment and provide the support and motivation needed to maintain long-term weight loss.

Weight-loss Journey at NextMed

NextMed is committed to helping people achieve health goals, and their science-backed FDA-approved medication and weight loss plans have helped thousands of members lose over 53 lbs on average. With NextMed, losing weight doesn't have to be complicated - it's easy to start, and their support team is always here to help. Don't wait - call today.

GLP-1a drugs, such as Doctor Prescribed Ozempic, Mounjaro, Saxenda, Rybelsus, Trulicy, Victoza, and Wegovy, are a type of medication that can help promote weight loss by increasing satiety and reducing appetite. Generic Contrave (Bupropion/Naltrexone) is another effective weight-loss drug. Metformin is also sometimes used for this purpose. All these medications used by NextMed are FDA-approved, with demonstrable weight loss in years-long clinical studies.

All these drugs can be effective when used properly, but it is essential to remember that they are not magic bullets. Weight loss still requires effort and lifestyle changes on the part of the individual. These drugs can help customers by giving the extra boost needed to achieve weight-loss goals.

Most customers lose an average of 23% of body weight. The average member has a starting weight of 230 pounds and can lose 53 pounds (23% weight loss). NextMed offers genuine doctors and a provider-led weight loss program. Additionally, monthly medical check-ups help track progress toward a goal while providing feedback about how things may be going otherwise.

NextMed's generic weight loss plan provides customers flexibility and control over goals. Looking for Wegovy Medication Online, contact us today and learn more on Weight Loss Medication Online!

Contact Information:
Frank Leonardo
Sr. Manager
[email protected]
914 426 1993


Press Release Service by Newswire.com

Original Source: Rising Obesity Rates; NextMed to the Rescue

Virgo is first investment for new GI fund.

CARLSBAD, Calif. - December 1, 2022 - (Newswire.com)

Virgo Surgical Video Solutions ("Virgo") today announced that the company received an investment from the American Gastroenterological Association ("AGA"), AGA's new venture capital fund, GI Opportunity Fund 1.  

"While AGA has long guided innovators who share our goal of improving digestive healthcare, we have doubled down on this commitment by establishing the GI Innovation Fund. The fund's first investment - Virgo - exemplifies our pursuit of improved clinical care," says Lawrence Kosinski, MD, AGAF, AGA Governing Board Councilor for Development and Growth. "Through our venture fund, gastroenterologists can join AGA to invest in fast-growing, early-stage companies that are transforming care for patients with digestive disease." 

Virgo provides gastroenterologists, clinical trial sponsors, and trial site investigators with AI-fueled, always-on endoscopic procedure recording and patient recruitment tools for clinical trials in gastroenterology, starting with inflammatory bowel disease clinical trials. 

"Virgo would not be where it is today without the support of the AGA, dating back to our initial pitch at the AGA Tech Summit's Shark Tank competition in 2018," said Matt Schwartz, Virgo co-founder and Chief Executive Officer. "Virgo is proud to have the support of the AGA, and this investment will help accelerate Virgo's mission to improve patient outcomes and clinical workflows by developing automation and AI tools for endoscopy." 

"As its partner in the GI Opportunity Fund, Varia shares the AGA's passion of supporting exciting innovations that benefit the GI field. Our partnership is designed, however, to do more than that. We firmly believe that this fund can also create an unusual opportunity for members interested in venture capital investing at an unusually low entry point. We believe we can accomplish these multiple objectives by making investments in companies like Virgo Surgical Video Solutions. Its video capture, management, and artificial intelligence analysis technology platform holds great promise for advancing the field of endoscopic medicine," said Scott Friedman, Varia Ventures co-founder and managing partner. 

More information about the AGA's GI Opportunity Fund 1 is available at https://againvest.varia.com/.  

About Virgo  

Virgo provides the leading cloud video capture, management, and artificial intelligence analysis platform for endoscopic medicine. Academic, integrated, and private practice healthcare providers use the Virgo platform to advance patient care through video-based research and training initiatives. Since launching, Virgo has helped physicians capture over 400,000 endoscopy procedures using industry-leading HIPAA, HITRUST, and SOC 2-compliant cloud service providers. Virgo also supports integration with all leading electronic health records systems. In 2021, Virgo launched a suite of tools called VirgoTrials, which help pharmaceutical trial sponsors and their participating trial sites accelerate patient recruitment and shorten the overall enrollment period for trials. For more information, visit www.virgosvs.com. 

About AGA  

The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, AGA has grown to more than 16,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization. For more information, visit www.gastro.org.  

The AGA Center for GI Innovation and Technology supports innovation and the development of new technology in gastroenterology, hepatology, nutrition and obesity by guiding medical device and therapeutics innovators through the technology development and adoption process. 

About Varia Ventures  

Varia Ventures is a next-generation venture capital platform for professional organizations interested in building wealth for themselves and their members through investing in a portfolio of highly curated, emerging companies originating from their organizations. Varia's platform blends insights from key opinion leaders, strategic partners, and industry experts through its "end-to-end" technology solution designed to both support early-stage companies while providing compelling investment opportunities to its investors. For more information, visit variaventures.com. 

Contact Information:
Jake Hungarter
Marketing
[email protected]
+14848960602


Press Release Service by Newswire.com

Original Source: AI-Fueled Endoscopy Capture and Clinical Trials Platform, Virgo Surgical Video Solutions, Receives Support From American Gastroenterological Association Venture Fund

New suite of time-saving products address pathology, cytology and histology laboratory staffing shortages and storage inefficiencies.

STERLING HEIGHTS, Mich. - December 1, 2022 - (Newswire.com)

SPOT Imaging proudly announces a new generation of sample-tracking and administration tools designed specifically to address today's staffing shortages and storage accuracy concerns. BlocDoc™, PathTracker™ and PathArchiv™ operate as an integrated system - or separately within existing lab systems - to significantly transform the efficiency and precision of the sample-tracking process.

Created in association with leading pathologists, SPOT Imaging's new product suite delivers cost savings and superior accuracy. Pathology, cytology and histology laboratories no longer need extensive teams of experienced laboratory technicians for sample handling.

BlocDoc™ turns physical paraffin blocks into digital assets for quick electronic sharing and tracking instead of a technician physically addressing and shipping samples. The digital assets make questions of tissue completeness trivial and routine rather than a labor-intensive, exceptional request, meeting the intent of the CAP Accreditation Committee when they added this requirement to the laboratory accreditation checklist. 

PathTracker™ bulk scans cassette and slide transport containers, across the histology process, ensuring the timely recovery of lost or late samples. Time-consuming and error-prone hand scanning is replaced with a simple image and electronic scan of the full container that is 8-18 times faster than hand scanning. Captured barcodes are automatically uploaded to an LIS.

PathArchiv™, a file room sample management system, virtually eliminates lost samples and saves 4-8 times the full-time equivalent technician resource, providing 30% greater storage density while fitting directly on most existing shelving units. When samples are loaned, PathArchiv™ automatically tracks the destination and return due date. Its non-sequential workflow filing methodology eliminates refiling costs.

"SPOT Imaging provides state-of-the-art technology to solve the most pressing problems administrators and pathologists face today: too few technicians to handle an overabundance of samples and data," states Philip Merlo, Vice President, SPOT Imaging. "Each of our new products will work with existing laboratory computing and storage infrastructure. Our collaboration with pathologists delivers products that meet real-world challenges in cost-effective and time-efficient ways."

On-site demonstrations of BlocDoc™, PathTracker™ and PathArchiv™ are available to laboratories endeavoring to achieve substantial cost-savings and greater tracking accuracy.  

About SPOT Imaging

SPOT Imaging provides end-to-end imaging solutions specifically designed for histology, cytology and pathology laboratories. The company's technologies substantially improve workflow efficiencies while increasing sample accuracy through the automated digitization of sample assets that provides the foundation for virtual sharing and tracking across the laboratory workflow and network user base.

Featuring proprietary designs and in-house manufacturing, SPOT Imaging is recognized worldwide for the ease of use, excellent performance and high reliability of its imaging products and end-to-end solutions. SPOT Imaging digital cameras and extended systems are integral to the operations of some of the most prestigious medical institutions, including Duke University, the University of Michigan, Stanford University, the Cleveland Clinic and the Mayo Clinic. For more information, visit www.spotimaging.com.

Contact Information:
Joni Jones
Marketing Manager
[email protected]
248-854-4378


Press Release Service by Newswire.com

Original Source: SPOT Imaging Announces Cost-Saving Sample Tracking, Storage and Management Solutions

Goynes-Brown Breaks Glass Ceiling as First Black Mayor in the State

LAS VEGAS - December 1, 2022 - (Newswire.com)

The City of North Las Vegas' new Mayor, Pamela Goynes-Brown, officially takes office today, becoming the first black Mayor in Nevada history. Goynes-Brown, a longtime educator turned public servant, previously served as Councilwoman of North Las Vegas' Ward 2 and was the first female African American Councilwoman in her previous role. She also was the first female African American Mayor Pro-Tempore, having served in that role twice. Goynes-Brown's recent election as Mayor continues her streak of breaking barriers. 

After referencing records via the University of Nevada Las Vegas (UNLV) School of Public Policy, the UNLV Oral History Research Center and relevant municipal leadership organizations, Goynes-Brown's victory sets a new precedent in Nevada's 158-year history and the approximately 400 mayoral elections of the State's 19 incorporated cities over that time.

Goynes-Brown leads the charge for the City of North Las Vegas, the third-largest municipality in Nevada and one of the largest minority-majority cities in America.

"Why has it taken so long?" Mayor Goynes-Brown asked. "I don't know, but I know it is happening right now and that is what's important — I'm so proud that the City of North Las Vegas has once again been the leader in making huge positive strides for our state and residents.

"It is an incredible honor to serve the constituents of the City of North Las Vegas, one of the most diverse cities in America," Goynes-Brown continued. "To set the stage for young boys and girls in North Las Vegas, to see themselves represented from the Mayor's seat to our Executive offices to the Team Members who serve our community each day, I believe the City of North Las Vegas embodies the beautifully diverse future of this country and I am honored to serve as Mayor." 

The City of North Las Vegas was the first municipality in the state to formally recognize June 19 as the Juneteenth holiday when the City Council passed Resolution 2665 in June 2021. That October, the North Las Vegas City Council approved updated contracts with employee bargaining units to add Juneteenth as an official City holiday and close City facilities in recognition. The City of North Las Vegas currently has a bill at the State Legislature proposing to make Juneteenth a State Holiday, as well as a bill proposing to allow people who are legally authorized to work in the United States to become peace officers, removing the requirement that they be a U.S. citizen.

"We must continue to call out institutional racism. We must continue to work to bring equity to all aspects of government. I look forward to working to continue to make strides for our community and for the people of color who call it home," said Mayor Goynes-Brown. "As I take office, the City of North Las Vegas will continue to advocate and prioritize our diverse residents and their needs."

For more information on all of these efforts and more, visit www.cityofnorthlasvegas.com.

About The City of North Las Vegas

North Las Vegas stretches across the northern rim of the Las Vegas Valley and is home to more than 275,000 residents. As a premier place to live, work and play, North Las Vegas leads the valley in new home development while maintaining a longstanding tradition of successful economic development in a business-friendly environment. The City of North Las Vegas' fast and faster approach has made the city a top destination in the country for development opportunities. North Las Vegas is a hub for new job creation and economic diversification that attracts global brands, innovative industries, manufacturing, e-commerce, and logistics centers.

Contact Information:
Cheryl Bella
PIO
[email protected]
702-499-3930

Brittany Toth
Director of Communications
[email protected]
702-218-0232


Press Release Service by Newswire.com

Original Source: City of North Las Vegas Mayor Makes Nevada History